NJ-SPIRENT-COMM
9.2.2021 09:02:10 CET | Business Wire | Press release
Spirent Communications plc (LSE:SPT), the leading provider of test, assurance, and analytics solutions for next-generation devices and networks, today released its second annual 5G outlook report, based on analysis and takeaways from over 600 global 5G engagements in 2020. The “5G 2021: Market Drivers, Insights & Consideration” report provides insights from across the 5G eco-system on the current status of 5G, illustrating the accelerated timetables from service providers in upgrading to 5G standalone (SA) with the new 5G Core, and revealing how 5G is driving new initiatives and sector engagements. The report is available at www.spirent.com/assets/the-spirent-2021-5g-report .
“2020 was certainly a year to remember, not just because of the unprecedented challenges presented by COVID-19, but also because of the rapid development for the telecom industry,” said Spirent Head of 5G Strategy, Steve Douglas. “Telecom is keeping its sights firmly focused on 5G’s future, not in spite of the challenges of the pandemic, but because of them, and our latest report gives an unparalleled view of the current status of 5G and the trends we’re seeing for the year ahead, based on the investments, research, testing and innovation by the leading 5G players.”
The report draws on Spirent’s work with operators, network equipment manufacturers, government, military, and device makers across the globe. It provides an updated, behind-the-scenes view of what’s gone right so far, where challenges persist, and how what was learned during the year is impacting priorities for 2021 and beyond. Key findings from the report include:
- 5G SA core timetables accelerated rapidly: 5G activity surged in 2020 with accelerated timetables from service providers to deliver 5G SA core deployments, following non-standalone’s (NSAs) inability to really wow customers and deliver a solid new revenue proposition. Service Provider engagement increased nearly 50% as Service Assurance integration ramped up, and leading operators accelerated 5G standalone network strategies and new 5G core deployments.
- Because 5G is moving so fast, operators are turning to partners to deliver key elements : Through service contracts, elements that would previously have been delivered inhouse are now being delivered by trusted partners, as operators need to be able to move quickly to keep up with the complexity of 5G and the accelerated timetables.
- 5G is driving new initiatives and engagements: The year saw notable growth in engagements with government, military and academia around 5G experimentation and security initiatives, as governments explore new use cases. Other notable initiatives include Cloud hyperscalers exploring operator edge partnerships, Open RAN being explored in support of supply chain diversity initiatives, and multichannel video programming distributors (MVPDs) accelerating their plans for 5G.
- Automated Assurance and 5G are the new dynamic duo: Whether it was a core network buildout, lab certification, or new service delivered, 5G plus Automated Assurance were the dynamic duo that customers turned to as they sought to continue pushing forward with their 5G plans, with 80% of Spirent’s assurance business focused on 5G work.
- The trend of accelerated timetables is here to stay: While the pandemic has undoubtedly accelerated 5G timetables, it seems likely this accelerated trend is here to stay.
“In many ways, the pandemic has accelerated trends that we hadn’t anticipated gaining steam for at least another couple of years,” said Douglas, “whether fixed wireless access driven by working from home, or automation required to safely conduct field testing with limited personnel. While there were delays, by and large 5G powered ahead and remained in control of its destiny.”
“Spirent provides us with a real-world glimpse into 5G deployments today,” said Patrick Kelly, Founder and Principal Analyst at Appledore Research. “Spirent has a unique perspective in the 5G ecosystem as a leader in test and assurance solutions. The report provides insights into the current status of 5G and what’s coming next, particularly in 5G core, transport, network security, Open RAN progress, and the role of automated assurance.”
Spirent’s “5G 2021: Market Drivers, Insights & Consideration ” report offers a broad view of market-wide 5G challenges, opportunities and plans, and is available as a download at https://www.spirent.com/assets/the-spirent-2021-5g-report .
About Spirent
Spirent Communications plc. (LSE: SPT) is the leading global provider of automated test and assurance solutions for networks, cybersecurity, and positioning. The company provides innovative products, services and managed solutions that address the test, assurance and automation challenges of a new generation of technologies, including 5G, SD-WAN, cloud, autonomous vehicles and beyond. From the lab to the real world, Spirent helps companies deliver on their promise to their customers of a new generation of connected devices and technologies. For more information, please visit www.spirent.com and follow us on LinkedIn , Twitter and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005179/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
